Stuart Weisman, MD
Rheumatology · Boulder, CONPI 1326022930
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 86.0% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $127 and has fallen 89.1% since, to $14 in 2025. That places this record below the midpoint for rheumatology clinicians in CO, where the typical reported total is $1,681.
Across 15 payments — averaging $15.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$203
- E.r. Squibb & Sons, L.L.C.$19
- UCB, Inc.$14
Across 1 payment — averaging $17.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$17
What the payments were for
- Food & beverage$235100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 13 | $203 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| UCB, Inc. | 1 | $14 |
How this compares
$235 in reported general payments places this provider in the 30th percentile of 108 rheumatology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 39 | $489,697 |
| Enbrel SureclickEtanercept | 43 | $342,444 |
| Cosentyx Sensoready PenSecukinumab | 20 | $237,800 |
| Xeljanz XrTofacitinib Citrate | 26 | $180,599 |
| Humira PenAdalimumab | 25 | $168,495 |
| EnbrelEtanercept | 22 | $156,173 |
| Orencia ClickjectAbatacept | 13 | $81,348 |
| MethotrexateMethotrexate Sodium | 379 | $11,066 |
| Hydroxychloroquine Sulfate | 159 | $7,462 |
| Celecoxib | 193 | $5,477 |
| Cevimeline Hcl | 39 | $5,067 |
| Leflunomide | 62 | $4,706 |
| Alendronate Sodium | 85 | $4,370 |
| Mycophenolate Mofetil | 22 | $3,914 |
| Gabapentin | 148 | $2,730 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Boulder
- James LevineGreeley$130K
- Aryeh FischerDenver$114K
- Adam BerlinbergDenver$94K
- David TheisColorado Springs$61K
- Rennie McCabeDenver$58K
- Larry MorelandAurora$55K
- Barbara GoldsteinDenver$47K
- Sterling WestAurora$42K
- Ndudi OparaecheEnglewood$36K
- Christopher AntoliniDenver$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.